Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	151
Overall Study	STARTED	Cariprazine 1.5 mg	145
Overall Study	STARTED	Cariprazine 3.0 mg	147
Overall Study	STARTED	Cariprazine 4.5 mg	148
Overall Study	STARTED	Risperidone 4.0 mg	141
Overall Study	COMPLETED	Placebo	79
Overall Study	COMPLETED	Cariprazine 1.5 mg	90
Overall Study	COMPLETED	Cariprazine 3.0 mg	96
Overall Study	COMPLETED	Cariprazine 4.5 mg	98
Overall Study	COMPLETED	Risperidone 4.0 mg	101
Overall Study	NOT COMPLETED	Placebo	72
Overall Study	NOT COMPLETED	Cariprazine 1.5 mg	55
Overall Study	NOT COMPLETED	Cariprazine 3.0 mg	51
Overall Study	NOT COMPLETED	Cariprazine 4.5 mg	50
Overall Study	NOT COMPLETED	Risperidone 4.0 mg	40

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00694707/flow